Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference

SOUTH PLAINFIELD, N.J., June 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy (SMA), at the 22nd...